ÂÜÀòÂÒÂ×

Dr. Kate Knobil is Agilent’s chief medical officer (CMO) and is responsible for advising, leading, and elevating Agilent’s presence in the health care industry. She is driving the expansion of Agilent’s leadership in precision medicine and supporting the development of novel therapeutics to improve patient outcomes.

Kate has more than 20 years of experience in clinical development and medical affairs while serving in strategic leadership roles across the globe. She has led development and medical affairs functions in the U.S., Europe, and in emerging markets.

Prior to joining Agilent, Kate served as CMO and head of research and development at Kaleido Biosciences, where she applied her pharmaceutical-development experience to guide the company in its approach to translating the promise of the microbiome into solutions for patients.

Her prior experience also includes tenure at GlaxoSmithKline, where she served in a variety of leadership roles, including the head of respiratory clinical development, head of late-stage clinical development in China, head of value evidence and outcomes, and CMO. During her time with GlaxoSmithKline, she represented the company at multiple health-regulatory agencies in several countries and led presentations for eight U.S. Food and Drug Administration Advisory Committee Meetings.

Kate received her bachelor’s degree from Cornell University and her medical degree from the University of Texas Southwestern Medical School. She also completed a fellowship in pulmonary and critical-care medicine at the Johns Hopkins University School of Medicine.

Kate is passionate about putting the needs of patients first, with the goal of bringing a heightened sense of purpose, motivation, and urgency to everyone in the company.